Özet:

Metabolic syndrome (MetS) refers to the concurrence of several known cardiovascular risk factors, including insulin resistance, obesity, atherogenic dyslipidemia, and hypertension. FGF-19, a peptide with 216 amino acids, including a signal peptide of 22 amino acids was recently introduced as a novel metabolic regulator reversing diabetes mellitus, hepatic steatosis, hyperlipidemia, and adiposity. Aim & Objective: To compare the serum Fibroblast Growth Factor 19 levels of metabolic syndrome patients with healthy individuals. To analyze the correlation between serum FGF 19 and the serum blood glucose levels of patients with MetS.

Anahtar Kelimeler: